Literature DB >> 1570486

Effect of physiotherapy on spinal mobility in ankylosing spondylitis.

J V Viitanen1, J Suni, H Kautiainen, M Liimatainen, H Takala.   

Abstract

The efficacy of intensive inpatient physiotherapy was retrospectively analysed in 505 adult patients with ankylosing spondylitis (AS). Eight different measures of thoracic and spinal mobility were collected from the patients' medical records. Recovery in terms of the following measures was 7 to 37% when results after rehabilitation were compared to those taken before: thoracolumbar flexibility (TLF) 15%, the Schober test 12.4%, occiput to wall distance (OWD) 30.8%, cervical rotation 22.6%, chin to chest distance (CCD) 21.7%, finger to floor distance (FFD) 36.6%, chest expansion (CE) 31.3%, vital capacity (VC) 7.4%. Changes in all measures were statistically significant (p less than 0.001). OWD, CE and FFD showed greatest improvement. The average increase in CE was about 1 cm in both sexes and the average increase in VC200 ml in men and 270 ml in women, which indicates improvement in ventilatory capacity. Mobility in the majority of patients improved, though in 2 to 8% range of motion (ROM) deteriorated during the course.

Entities:  

Mesh:

Year:  1992        PMID: 1570486     DOI: 10.3109/03009749209095061

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  12 in total

1.  Improvement in pain intensity, spine stiffness, and mobility during a controlled individualized physiotherapy program in ankylosing spondylitis.

Authors:  Zsuzsanna Némethné Gyurcsik; Anita András; Nóra Bodnár; Zoltán Szekanecz; Sándor Szántó
Journal:  Rheumatol Int       Date:  2011-12-25       Impact factor: 2.631

2.  Intra-tester and inter-tester reliability of chest expansion measurement in clients with ankylosing spondylitis and healthy individuals.

Authors:  Jagannath Sharma; Hideaki Senjyu; Linda Williams; Colin White
Journal:  J Jpn Phys Ther Assoc       Date:  2004

3.  Fifteen months' follow-up of intensive inpatient physiotherapy and exercise in ankylosing spondylitis.

Authors:  J V Viitanen; K Lehtinen; J Suni; H Kautiainen
Journal:  Clin Rheumatol       Date:  1995-07       Impact factor: 2.980

4.  Assessment of muscle shortening and static posture in children with persistent asthma.

Authors:  Erica A Lopes; Adriana Fanelli-Galvani; Camilla C V Prisco; Raquel C Gonçalves; Cristina M A Jacob; Anna L B Cabral; Milton A Martins; Celso R F Carvalho
Journal:  Eur J Pediatr       Date:  2006-11-16       Impact factor: 3.183

Review 5.  Current guidelines for the drug treatment of ankylosing spondylitis.

Authors:  E Toussirot; D Wendling
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

6.  [Physiotherapeutic and rehabilitation therapy for ankylosing spondylitis. Status quo and are they still necessary in the age of anti-cytokine therapy?].

Authors:  U Lange; B Kürten; U Müller-Ladner; C Uhlemann
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

7.  Treatment of ankylosing spondylitis with biologics and targeted physical therapy: positive effect on chest pain, diminished chest mobility, and respiratory function.

Authors:  Z Gyurcsik; N Bodnár; Z Szekanecz; S Szántó
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

8.  Recovery after stabilising surgery for 'flail chest'.

Authors:  M Fagevik Olsén; D Pazooki; H Granhed
Journal:  Eur J Trauma Emerg Surg       Date:  2013-04-30       Impact factor: 3.693

9.  The Anthropometric Measurement of Schober's Test in Normal Taiwanese Population.

Authors:  Yong-Ren Yen; Jin-Fan Luo; Ming-Li Liu; Fung-Jou Lu; Soo-Ray Wang
Journal:  Biomed Res Int       Date:  2015-07-27       Impact factor: 3.411

10.  Combined home exercise is more effective than range-of-motion home exercise in patients with ankylosing spondylitis: a randomized controlled trial.

Authors:  Lin-Fen Hsieh; Chih-Cheng Chuang; Ching-Shiang Tseng; James Cheng-Chung Wei; Wei-Chun Hsu; Yi-Jia Lin
Journal:  Biomed Res Int       Date:  2014-09-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.